Current evaluation of alemtuzumab in multiple sclerosis

Bibliography

• O'Gorman C, Lucas R, Taylor B. Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci 2012;13:11718-52
   PubMed Web of Science ®Google Scholar
• Trojano M, Lucchesse G, Graziano G, et al. Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012;7:e48078
   PubMed Web of Science ®Google Scholar
• Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci 2009;277(51):542-5
   Google Scholar
• Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: Why? When? How? CNS Drugs 2013;27:403-9
   PubMed Web of Science ®Google Scholar
• Coles AJ. Alemtuzumab treatment of multiple sclerosis. Semin Neurol 2013;33:66-73
   PubMed Web of Science ®Google Scholar
• Ali R, Nicholas RSJ, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013;73:625-50
   PubMed Web of Science ®Google Scholar
• Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis – a focus on alemtuzumab. Clin Immunol 2012;142:25-30
   PubMed Web of Science ®Google Scholar
• Bandala-Sanchez E, Zhang Y, Reinwald S, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol 2013;14:741-8
   PubMed Web of Science ®Google Scholar
• Rao SP, Sancho J, Campos-Rivera J, et al. Human peripheral blood mononuclear cells exhibit heterogenous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012;7:e39416
   PubMed Web of Science ®Google Scholar
• Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:298-304
   PubMed Web of Science ®Google Scholar
• Warner JL, Arnason JE. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol 2012;3:375-89
   PubMedGoogle Scholar
• Kousin-Ezewu O, Coles A. Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. Ther Adv Chronic Dis 2013;4:97-103
   PubMedGoogle Scholar
• Perumal JS, Foo F, Cook P, et al. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. MSJ 2012;18:1197-9
   Google Scholar
• Moreau T, Scolding N, Compston A, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298-301
   PubMed Web of Science ®Google Scholar
• Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108
   PubMed Web of Science ®Google Scholar
• Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-8
   PubMed Web of Science ®Google Scholar
• CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
   PubMed Web of Science ®Google Scholar
• Graves J, Galetta SL, Palmer J, et al. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis. MSJ 2013;19:1302-9
   Google Scholar
• Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338-48
   PubMed Web of Science ®Google Scholar
• Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon- beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069-78
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CI, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• Krieger S, Arnold DL, Cohen JA, et al. Alemtuzumab is efficacious in highly active relapsing-remitting multiple sclerosis patients [abstract DX01]. CMSC Annual Meeting DXOI; 2013
   Google Scholar
• Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012;19:307-11
   PubMed Web of Science ®Google Scholar
• Cossbaum M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77:573-9
   PubMed Web of Science ®Google Scholar
• Aranha AA, Amer S, Reda ES, et al. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review. Endocr Pract 2013;19(5):821-8
   PubMed Web of Science ®Google Scholar
• Costelloe L, Jones J, Coles A, et al. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother 2012;12:335-41
   PubMed Web of Science ®Google Scholar
• Coles AJ. Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics 2013;10:29-33
   PubMed Web of Science ®Google Scholar
• Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-61
   PubMed Web of Science ®Google Scholar
• Brown JWL, Coles AJ. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther 2013;7:131-8
   PubMed Web of Science ®Google Scholar